This website uses cookies. By continuing you are agreeing to our privacy policy.

Andrew Haak, Ph.D.

Andrew Haak
Mayo Clinic
Catecholamine Signaling Regulates Pulmonary Fibrosis
Catalyst Award

Idiopathic pulmonary fibrosis (IPF) is an aggressive and fatal disease that causes scarring (fibrosis) of the lungs. Scarring causes stiffness in the lungs and makes it difficult to breathe. Lung damage from IPF is irreversible and progressive, meaning it gets worse over time. The processes that promote the chronic nature and prevent resolution of pulmonary fibrosis are not understood. We will investigate the role hormones called catecholamines (dopamine, norepinephrine and epinephrine) play in regulating pulmonary fibrosis. We will study how catecholamine cell signaling regulates the disease and test clinically approved drugs which regulate catecholamines in models of pulmonary fibrosis. The results could lead to a potential treatment that not only halts the progression of fibrosis but promotes its reversal and improves lung function.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl
What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.